Cancer Research UK Standardizes on Phase Forward’s InForm™ Global Trial Management Solution
December 16 2009 - 9:00AM
Business Wire
Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, today
announced that Cancer Research UK’s Drug Development Office – the
drug development arm of the world’s largest independent
organization dedicated to cancer research – is standardizing on
Phase Forward’s InForm™ Global Trial Management solution to support
its diverse portfolio of early-stage clinical trials. The
announcement marks a multi-year agreement between Phase Forward and
the prestigious research organization.
Cancer Research’s Drug Development Office plans to use the
InForm data capture solution to manage up to ten highly specialized
trials each year. The organization has pioneered the development of
some of the most novel anti-cancer treatments in the marketplace,
such as temozolomide, widely recognized as the gold standard
treatment for most cases of glioma – the most common form of brain
cancer.
In late spring, Cancer Research UK’s Drug Development Office
initiated a formal evaluation process as part of its Clinical
Operations ReEngineering (CORE) project, an initiative that aims to
deliver high-quality data faster, with the goal of beating cancer.
As part of this initiative, the organization set out to select a
best-of-breed electronic data capture (EDC) product, working with
multiple vendors to find the ideal business and technical partner
to meet the organization’s requirements.
After an extensive evaluation, the Drug Development Office
selected Phase Forward’s InForm solution, based on the partnership
approach and flexibility demonstrated by Phase Forward’s global
services team. Other key factors included technical strength and
scalability of the product, the company’s broad experience with
oncology trials and the availability of investigators trained in
using InForm.
“Information is key to our success in managing early stage
clinical trials, so it is vital that we invest in the technology to
support this important work,” said Dr. Nigel Blackburn, director of
Cancer Research UK’s Drug Development Office. “We were particularly
impressed with Phase Forward’s commitment to addressing our
requirements, as well as the company’s experience in developing the
data capture tools to manage these trials.”
“Cancer Research UK is one of the most respected organizations
in the world, advancing the cause of cancer prevention, diagnosis
and treatment,” said Bob Weiler, chairman and CEO, Phase Forward.
“We’re honored to work with their dedicated team of professionals
to help deliver the next generation of cancer treatments.”
The organization’s first study using the InForm solution will
compare two treatments for metastatic prostate cancer.
About Cancer Research UK’s Drug Development Office
Cancer Research UK has an impressive record of developing novel
treatments for cancer. It currently has a portfolio of around 40
new anti-cancer agents in preclinical development, Phase I or early
Phase II clinical trials. Since 1982, the Cancer Research UK’s Drug
Development Office has taken over 100 potential new anti-cancer
agents into clinical trials in patients, five of which have made it
to market and many others are still in development. These include
temozolomide, a drug discovered by Cancer Research UK scientists,
that is an effective new treatment for brain cancer. Six other
drugs are in late development Phase III trials.
For further information about Cancer Research UK’s work or to
find out how to support the charity, please call 020 7121 6699 or
visit www.cancerresearchuk.org.
About Phase Forward
Phase Forward is a leading provider of integrated data
management solutions for clinical trials and drug safety. Phase
Forward’s products and services have been utilized in over 10,000
clinical trials involving more than 1,000,000 clinical trial study
participants at over 300 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber
Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and
Healthcare Products Regulatory Agency. Additional information about
Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. This press release
contains express or implied forward-looking statements relating to,
among other things, the performance and features of Phase Forward's
products and services, demand for Phase Forward's products and
services, future business and operations plans of a Phase Forward
customer, and the ability of Phase Forward's customers to realize
benefits from the use of Phase Forward's products and services.
These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are
beyond Phase Forward's control, which could cause actual results to
differ materially from those contemplated in these forward-looking
statements. In particular, the risks and uncertainties include,
among other things, the ability of Phase Forward's customers to
realize benefits from the use of its products and services, the
possibility that customers' needs or plans may change over time,
the possibility that the level of demand for Phase Forward's
products and services may vary, regulatory changes and competition.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or
circumstances or otherwise. For additional disclosure regarding
these and other risks faced by Phase Forward, see the disclosure
contained in Phase Forward's public filings with the Securities and
Exchange Commission including, without limitation, its most recent
Annual Report on Form 10-K.
Information contained in this release regarding Cancer Research
UK and temozolomide has been supplied by Cancer Research UK and
Phase Forward Incorporated takes no responsibility for the accuracy
or completeness thereof.
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jul 2023 to Jul 2024